Kornimate/medical-research-clean huggingface dataset:
eras in laparoscopic surgery for colorectal cancer: risk factors for delayed recovery

Conditions: Colonic Neoplasms; Laparoscopy; Perioperative Care

Summary: although there is evidence for reducing complication rate and improving recovery after the implementation of enhanced recovery after surgery (eras) protocols into colorectal surgery, most published papers include patients undergoing open resections. the aim was to analyse factors affecting recovery and length of stay (los) in patients after laparoscopic colorectal surgery for cancer combined with eras protocol.

all patients were operated using laparoscopic surgery, and the perioperative care was based on pre-established eras protocol consisting of 13 pre and intraoperative items. its principles and criteria for discharge from the hospital were based on the eras society guidelines. investigators analysed which of the factors: gender; age; bmi; asa (american society of anaesthesiologists) physical status; type of surgery (colonic resection vs. rectal resection with total mesorectal excision, tme); stage of cancer; distance between the hospital and place of residence; operative time; intraoperative blood loss significantly prolong los (primary length of stay, excluding readmissions). moreover, the compliance with eras protocol and its influence on los was analysed. for the purposes of further analyses the entire group of patients was divided into 2 subgroups depending on the length of their hospital stay. on admission every patient received the information about the target length of stay of 4 days. group 1 consisted of patients whose hospital stay was shorter or equal to the target los (≤ 4 days). in group 2 were patients whose hospital stay was longer than 4 days.

Eligibility criteria:
inclusion criteria: * colorectal cancer * laparoscopic resection * perioperative care according to eras principles exclusion criteria: * patients submitted initially for open or emergency surgery * with complex cancer who required multi-organ resection * patients treated with endoscopic techniques using the hybrid tatme technique (transanal total mesorectal excision)

Keywords: colorectal cancer enhanced recovery after surgery perioperative care fast-track surgery laparoscopy minimally invasive surgery complications
study of structural and functional brain connectivity changes in als (coals-ii)

Conditions: Amyotrophic Lateral Sclerosis

Summary: this study will try to understand the difference in brain structure between als patients and healthy people of similar age. als is a condition affecting the nervous system with disruption of the brain networks. this study aims to understand these disruptions and determine their significance in als.

participants and healthy controls will be consented into the study. after consent, details including age, duration of disease, alsfrs score, and grip strength will be collected. participants will be trained to perform a grip and release task using a foam ball for 1 minute while inside an mri scanner. anatomical, functional and diffusion mri sequences will be acquired during the scanning, and total scan time will be approximately 1 hour.

Eligibility criteria:
inclusion criteria: * based on el escorial criteria we will select probable or definite als. * healthy controls age matched to als patients * subjects should be able to lie down in a scanner and undergo an hour-long mri study * subjects should be able to understand instructions, provide consent and perform a hand task while inside the scanner exclusion criteria: * unable to undergo mri due to any reason * age \<18 * als patients having high aspiration risk * patients having cognitive limitations which prevents them from understanding the study requirements, providing consent or perform tasks inside the scanner.

Keywords: amyotrophic lateral sclerosis functional magnetic resonance imaging connectivity diffusion tensor imaging dynamometer
assessing tenapanor as a treatment of cf-related constipation.

Conditions: Cystic Fibrosis; Constipation

Summary: tenapanor is the newest fda-approved drug for ibs with constipation (ibs-c). this study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (cfrc) in cf patients. participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. they will also complete three questionnaires, the pac-sym, pac-qol, and ibs-sss, and daily diaries to characterize gi symptom burden and spontaneous bowel movement (sbm) frequency.


Eligibility criteria:
inclusion criteria: 1. having confirmed cystic fibrosis (either by sweat chloride or genetic testing) 2. meeting criteria for cfrc must include 2 of the following, with or without abdominal pain for at least 3 months, with symptom onset at least 6-months prior: * straining in at least 25% of defecations * bristol stool scale 1-2 more than 25% of defecations (change in stool form) * sensation of incomplete evacuation more than 25% of defecations * sensation of anorectal obstruction/blockage more than 25% of defecations * manual disimpaction/manipulation of pelvic floor to facilitate more than 25% of defecations * fewer than 3 spontaneous bowel movements weekly (change in stool frequency) * loose stools rarely present without the use of laxatives 3. willingness to avoid major dietary or lifestyle changes during study. exclusion criteria: 1. use of any antibiotic to treat infection within the 4-weeks prior to study initiation (stable azithromycin dosed 3-times weekly for lung function is to be allowed) 2. inability to discontinue standing bowel regimen (including fiber, stool softener, as well as either osmotic or stimulant laxative, pro-kinetic serotonergic agents, or other therapy) 2-weeks prior to study drug initiation (with ability to use osmotic laxative therapy as rescue therapy only). 3. severe cfrc as determined by study team 4. prior tenapanor usage 5. hospitalization within 4-weeks prior to study initiation. 6. dios within 4-weeks prior to study initiation. 7. other known/suspected mechanical obstruction

Keywords: constipation cystic fibrosis cfrc
anesthetic efficacy in irreversible pulpitis

Conditions: Anesthesia

Summary: the purpose of this study was to compare the anesthetic efficacy of articaine, lidocaine and mepivacaine in patients with irreversible pulpitis of mandibular molar.

conventional inferior alveolar nerve block (ianb) is the most commonly used technique for achieving pulpal anesthesia in posterior mandibular endodontic procedures. however, ianb has a high failure rate and success rates are even lower when applied for the treatment of mandibular posterior teeth with irreversible pulpitis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of irreversible pulpitis * good health * had at least 1 adjacent tooth plus a healthy canine exclusion criteria: * took medication could be interacting with any of the anesthetics used

Keywords: articaine lidocaine mepivacaine inferior alveolar nerve block irreversible pulpitis
needless laser injector for antiaging effect of dermal filler

Conditions: Aging Problems

Summary: the investigators aimed to evaluate the efficacy and safety of needless laser injector for antiaging effect of dermal filler.

a 24-week prospective, single-center, assessor-blinded, randomized, split-face study was conducted to compare the clinical efficacy and safety of needless laser injector versus needle injection for anti-aging effect of dermal filler.

Eligibility criteria:
inclusion criteria: * patients who wanted to improve facial skin aging exclusion criteria: * a history of skin rejuvenation treatment (including filler, botulinum toxin, lasers, chemical peeling, and topical retinoid) within 6 month prior to the start of the study * having a plan for skin rejuvenation treatment during the study * current pregnancy or breastfeeding * an allergy to polylactic acid (pla) or hyaluronic acid (ha) * uncontrolled medical diseases
brain health in the time of covid-19

Conditions: Brain Health

Summary: this is a nationwide research program to study the neurological effects of covid-19. it is open to the public. healthy individuals and individuals who are or have been infected with covid-19 are encouraged to join the effort. the study can be done at home with internet access and an ipad or iphone. participation takes about one hour. to learn more, go to https://www.mirohealth.com/consent/

neurological complications have been reported in patients with covid-19. to better understand neurological complications, a group of research hospitals are collaborating to track neurological outcomes. we know that covid-19 can invade our nervous system, but little is known about the range of effects that covid-19 might have on the brain. this study aims to gain real-time information about the neurological health of the u.s. population to advance knowledge of covid-19. at the conclusion of the study, you will receive non-medical information on your brain function as well as study findings and publications made possible by your participation. with your permission, miro health can also release the results of your assessment to your physician. in order for miro health to do this, you will be required to confirm your identity online, sign a hipaa agreement to share the information with your physician, and to enter your physician's name, email, and contact information. study duration will depend on the development of the covid-19 pandemic. to participate, you must submit a valid email. no other personally identifiable information will be gathered at this time. to participate, you will: answer online questions answer a few questions about your health download the miro health app from the itunes store open the app and complete miro's interactive tasks (30 mins) advisory: should you feel that you have symptoms related to covid-19, contact your healthcare provider or local community health office. miro health cannot provide healthcare assistance.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * access to an ipad bought in 2013 or later * access to stable wi-fi * access to itunes exclusion criteria for healthy: * below age 18 * preexisting neurological, psychiatric, or developmental disorder

Keywords: covid-19 neurocognitive stroke nervous system
a study reviewing medical records of adults with helicobacter pylori infections in china

Conditions: Helicobacter Pylori

Summary: the main aim of the study is to review treatment therapies in people with helicobacter pylori (h. pylori) infections in standard hospital settings in china. in this study, the study doctors will review medical records of participants who have had h. pylori infections any time from 1st january 2019 to 31st december 2021. this study is about collecting existing data only; participants are not treated and do not need to visit a study doctor during this study.

this is a non-interventional, retrospective cohort study of participants who have evidence of h. pylori infection using pre-existing electronic medical record data in china. this study will evaluate the distribution of methods of eradication therapy among participants who received medications that were used in the eradication therapy for h. pylori infection. retrospective de-identified participant-level data will be collected primarily from hospitals in china between 1st january 2019 to 31st december 2021. the extracted electronic medical record dataset will include patient demographic information, visit information, diagnosis information, treatment information, and cost information (if available). all the participants will be assigned to a single observational cohort: • participants with h. pylori this multi-center study will be conducted in china. the overall study duration will be approximately 54 months.

Eligibility criteria:
inclusion criteria: 1. participants with a record of h. pylori infection diagnosis or positive result of h. pylori diagnostic testing between 1st january 2019 and 31st december 2021. exclusion criteria: not applicable.

Keywords: drug therapy
classification of carotid plaque with computed tomography with fast kvp (kilovolt peak)-switching technique

Conditions: Atherosclerosis; Carotid Stenosis

Summary: classification of carotid plaque vessel wall changes in carotid stenosis accordingly to aha classification (american heart association)- comparison between histology and ct. the ct is performed with a fast kvp-switching dual energy technique. to compare the ability to detect iodine contrast enhancement in the carotid plaque compared with 3t mri with gadolinium.

patients planned for cea (carotid endarterectomy) due to carotid stenosis will be examined with one extra ct and mri before surgery. the cea specimen is stored in the bike-registry (a biobank of operated carotid plaque at the karolinska institute). in that registry the patients will be given a personal code which is used to identify the ct, mri and histology data further on. approved by regional ethical review board in stockholm and local radiation comity at karolinska university hospital solna (dnr k2435-2014). informed consent from the participating patients.

Eligibility criteria:
inclusion criteria: * 50% stenosis (nascet) or more based on cta (ct-angiography), * mri or us, * scheduled for cea * 50 years or older, * normal kidney function (estimated gfr (glomerular filtration rate) 60 ml/min or more). exclusion criteria: * contraindications to iodine contrast media, * contraindications to mri or gadolinium contrast media.
effect of antioxidant docosahexaenoic acid (dha) in cystic fibrosis patients

Conditions: Cystic Fibrosis in Children

Summary: this study evaluates the effect of antioxidant docosahexaenoic acid (dha) in patients with cystic fibrosis. half of participants will receive dha, while the other half will receive placebo.

several studies show that patients with cystic fibrosis (cf) usually have, compared to the normal population, low levels of linoleic acid (la) and docosahexaenoic acid (dha) and increase in arachidonic acid (aa), which is pro-inflammatory. normalization or modification of this fatty acid pattern (ap) could reduce chronic inflammation. the aim of this study is to assess the effect of oral supplementation with dha for one year in pediatric patients (6-18 years) with cf, on inflammatory parameters, ap profile, lung function (spirometry) and number of exacerbations.

Eligibility criteria:
inclusion criteria: * patients of both genders with a diagnosis of cystic fibrosis. * fev1 \> 40%. * age between 6 and 18 years. * patients who grant their informed consent or whose representative grants informed consent to participate in the study. exclusion criteria: * pregnant or breastfeeding women * basal oxygen saturation \<92% or household supplemental oxygen needs. * massive hemoptysis * patients who are not able to follow or who cannot be assessed in the study according to the protocol. * any circumstance that, at the discretion of the doctor, may involve a clinical risk or harm, the patient's participation in the study or that interferes with the evaluation of the same. * use of systemic glucocorticoids or in the 4 weeks prior to inclusion in the study. * use of non-steroidal anti-inflammatory drugs in the 2 weeks prior to inclusion in the study. * use of investigational drugs or participation in another clinical trial within 30 days prior to inclusion in the study or within the 5 elimination half-lives of the investigational drug. * be already supplementing with omega -3, fish oil or dha

Keywords: cystic fibrosis docosahexaenoic acid fatty acids
investigation of weight loss and body composition changes after dosing with either placebo or one of two active drugs

Conditions: Diabetes Mellitus, Type 2; Obesity

Summary: the drugs gsk189075 and gw869682 result in increased caloric losses. this study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body. the body composition (fat,water, lean mass) is determined using a new investigational mr technology.


Eligibility criteria:
inclusion criteria: * bmi of 30 - 40kg/m * females may be included if they are surgically sterile or post-menopausal exclusion criteria: * change in body weight \>4% in the last 3 months * history of eating disorders * had bariatric surgical intervention for obesity * have type i or ii diabetes * thyroid disorder not under control * renal or hepatobiliary disease * excessive alcohol consumption * use of drugs of abuse * donated of blood in the last 3 months

Keywords: body composition obesity 4c model hunger weight loss
patient considerations of social media account management after death

Conditions: Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid System Neoplasm

Summary: this study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death. collecting information on the use of social media and preferences will allow for a better understanding of patient's needs in the dying process and may identify populations in need of education, identify a possible source of anxiety and stress, and allow for an informed discussion of digital legacy.

primary objective: i. identify the proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account (e.g. facebook, twitter, instagram) management after death. secondary objective: i. identify the proportion of social media participation among advanced cancer patients seen in the supportive care clinic. ii. evaluate the baseline awareness advanced cancer patients seen in the supportive care clinic have regarding how their facebook account may be managed after death. iii. evaluate affect changes and distress as a result from the conversation regarding their social media account management after death. iv. evaluate if discussion of social media account management among patients with advanced cancer in the supportive cancer clinic will increase their awareness of and motivation to address their social media account management options. outline: patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.

Eligibility criteria:
inclusion criteria: * patients with at least 1 follow-up visit to the outpatient supportive care clinic at mdacc * patients with any type of advanced cancer * patients aged 18 years or older * patients who have used social media * patients able to read and write in english exclusion criteria: * delirium as diagnosed by treating supportive care center (scc) physician or memorial delirium assessment scale (mdas) score \>= 7
a study of topical steroids as preemptive therapy for egfr inhibitor-induced papulopustular eruption

Conditions: Acneiform Rash; Papulopustular Eruption

Summary: this randomized, controlled, phase ii clinical study is designed to assess the efficacy of preemptive treatment with topical steroids in preventing the papulopustular eruption induced by epidermal growth factor receptor inhibitor (egfri) treatment in cancer patients. participants will be followed up for 6 weeks of twice daily application of triamcinolone cream to the face, chest, and back.


Eligibility criteria:
inclusion criteria: * patients must have a histologically or cytologically confirmed cancer diagnosis for which egfri treatment is indicated * initiation of topical steroids or control treatment within 3 days of initiation of cetuximab, erlotinib, panitumumab, or afatinib * patients must be age ≥ 18 years. * life expectancy of greater than 6 weeks * patient able to use topical medications reliably and complete questionnaires with assistance if needed * patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study. exclusion criteria: * patients who have used systemic or topical steroids within 7 days of trial registration, or start systemic or topical steroids for reasons unrelated to trial during the 6-week follow up period * patients who have used antibiotics within 7 days of trial registration, or start antibiotics for other conditions during the 6-week follow up period * history of allergic reactions to topical steroids * patients with any rash at the time of study registration * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * patients using any other topical medications in the treatment areas (face, chest, or back).
role of obstructive sleep apnea syndrome in the occurrence of diabetic retinopathy in type 2 diabetes.

Conditions: Diabetes Mellitus; Obstructive Sleep Apnea

Summary: diabetic retinopathy (dr) is the most common visual complication of diabetes. risk factors for developing dr are diabetes duration, glycemic control, and hypertension . the prevalence ranges from 17 to 61% according to the diabetes duration . obstructive sleep apnea syndrome (osas) is very frequent in type 2 diabetes population, reaching a prevalence of 23-48% . few is known about the exact role of osas in the development of dr. a recent study has shown that osas is an independent predictor for the progression to pre-/proliferative dr. the purpose of the present study is to assess if the presence of osa in diabetic patients is a predictive factor for dr occurrence.

diabetic retinopathy (dr) is the most common visual complication of diabetes. risk factors for developing dr are diabetes duration, glycemic control, and hypertension. the prevalence ranges from 17 to 61% according to the diabetes duration. obstructive sleep apnea syndrome (osas) is very frequent in type 2 diabetes population, reaching a prevalence of 23-48%. few is known about the exact role of osas in the development of dr. a recent study has shown that osas is an independent predictor for the progression to pre-/proliferative dr. the purpose of the present study is to assess if the presence of osa in diabetic patients is a predictive factor for dr occurrence.

Eligibility criteria:
inclusion criteria: * presence of diabetic type ii * able to undergo an in-lab polysomnography exclusion criteria: * known presence of obstructive sleep apnea and treated by cpap

Keywords: diabetic retinopathy diabetes arterial hypertension obstructive sleep apnea syndrome